Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021Business Wire • 01/07/21
Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast CancerBusiness Wire • 12/11/20
Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer SymposiumBusiness Wire • 12/08/20
Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual MeetingBusiness Wire • 12/07/20
Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020Business Wire • 11/09/20
Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual MeetingBusiness Wire • 11/05/20
Seagen's (SGEN) CEO Clay Siegall on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/30/20
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020Business Wire • 10/13/20